APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peripherally Acting Anti-Obesity Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Peripherally Acting Anti-Obesity Drug Market Analysis and Forecast 2026-2032

21 December 2025193 pages

Choose your research edition.

Industry ResearchPeripherally Acting Anti-Obesity Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Peripherally Acting Anti-Obesity Drug Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Peripherally Acting Anti-Obesity Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peripherally Acting Anti-Obesity Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Peripherally Acting Anti-Obesity Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Peripherally Acting Anti-Obesity Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Peripherally Acting Anti-Obesity Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Peripherally Acting Anti-Obesity Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Peripherally Acting Anti-Obesity Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Peripherally Acting Anti-Obesity Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Peripherally Acting Anti-Obesity Drug include Novo Nordisk A/S, Pfizer Inc., GlaxoSmithKline plc, Vivus LLC., Rhythm Pharmaceuticals, KVK Tech Inc., Gelesis Holdings, Currax Pharmaceuticals LLC and CHEPLAPHARM Arzneimittel GmbH, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Peripherally Acting Anti-Obesity Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Peripherally Acting Anti-Obesity Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Peripherally Acting Anti-Obesity Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peripherally Acting Anti-Obesity Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Peripherally Acting Anti-Obesity Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Peripherally Acting Anti-Obesity Drug sales, projected growth trends, production technology, application and end-user industry.

Peripherally Acting Anti-Obesity Drug Segment by Company

Novo Nordisk A/S

Pfizer Inc.

GlaxoSmithKline plc

Vivus LLC.

Rhythm Pharmaceuticals

KVK Tech Inc.

Gelesis Holdings

Currax Pharmaceuticals LLC

CHEPLAPHARM Arzneimittel GmbH

Boehringer Ingelheim International GmbH

Peripherally Acting Anti-Obesity Drug Segment by Type

Prescription Drugs

Non-prescription Drugs

Peripherally Acting Anti-Obesity Drug Segment by Application

Online Pharmacies

Hospital Pharmacies

Retail Pharmacies

Peripherally Acting Anti-Obesity Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peripherally Acting Anti-Obesity Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peripherally Acting Anti-Obesity Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peripherally Acting Anti-Obesity Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Peripherally Acting Anti-Obesity Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Peripherally Acting Anti-Obesity Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peripherally Acting Anti-Obesity Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Peripherally Acting Anti-Obesity Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Prescription Drugs Major Manufacturers Table 3. Non-prescription Drugs Major Manufacturers Table 4. Global Peripherally Acting Anti-Obesity Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Online Pharmacies Major Manufacturers Table 6. Hospital Pharmacies Major Manufacturers Table 7. Retail Pharmacies Major Manufacturers Table 8. Peripherally Acting Anti-Obesity Drug Industry Trends Table 9. Peripherally Acting Anti-Obesity Drug Industry Drivers Table 10. Peripherally Acting Anti-Obesity Drug Industry Opportunities and Challenges Table 11. Peripherally Acting Anti-Obesity Drug Industry Restraints Table 12. Global Peripherally Acting Anti-Obesity Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Peripherally Acting Anti-Obesity Drug Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Peripherally Acting Anti-Obesity Drug Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Region (2021-2026) Table 16. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Region (2027-2032) Table 17. Global Peripherally Acting Anti-Obesity Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 18. Global Peripherally Acting Anti-Obesity Drug Sales by Region (2021-2026) & (k units) Table 19. Global Peripherally Acting Anti-Obesity Drug Sales by Region (2027-2032) & (k units) Table 20. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Region (2021-2026) Table 21. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Region (2027-2032) Table 22. Global Peripherally Acting Anti-Obesity Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Peripherally Acting Anti-Obesity Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Manufacturers (2021-2026) Table 26. Global Peripherally Acting Anti-Obesity Drug Sales Price (US$/unit) of Manufacturers (2021-2026) Table 27. Global Peripherally Acting Anti-Obesity Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Peripherally Acting Anti-Obesity Drug Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Peripherally Acting Anti-Obesity Drug Manufacturers, Product Type & Application Table 30. Global Peripherally Acting Anti-Obesity Drug Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Peripherally Acting Anti-Obesity Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Peripherally Acting Anti-Obesity Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Peripherally Acting Anti-Obesity Drug Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Peripherally Acting Anti-Obesity Drug Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Type (2021-2026) Table 37. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Type (2027-2032) Table 38. Global Peripherally Acting Anti-Obesity Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 39. Global Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2026) & (k units) Table 40. Global Peripherally Acting Anti-Obesity Drug Sales by Type (2027-2032) & (k units) Table 41. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2021-2026) Table 42. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2027-2032) Table 43. Global Peripherally Acting Anti-Obesity Drug Price by Type (2021-2026) & (US$/unit) Table 44. Global Peripherally Acting Anti-Obesity Drug Price by Type (2027-2032) & (US$/unit) Table 45. Global Peripherally Acting Anti-Obesity Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Peripherally Acting Anti-Obesity Drug Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Peripherally Acting Anti-Obesity Drug Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Application (2021-2026) Table 49. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Application (2027-2032) Table 50. Global Peripherally Acting Anti-Obesity Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 51. Global Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2026) & (k units) Table 52. Global Peripherally Acting Anti-Obesity Drug Sales by Application (2027-2032) & (k units) Table 53. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2021-2026) Table 54. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2027-2032) Table 55. Global Peripherally Acting Anti-Obesity Drug Price by Application (2021-2026) & (US$/unit) Table 56. Global Peripherally Acting Anti-Obesity Drug Price by Application (2027-2032) & (US$/unit) Table 57. Novo Nordisk A/S Company Information Table 58. Novo Nordisk A/S Business Overview Table 59. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 60. Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product Portfolio Table 61. Novo Nordisk A/S Recent Development Table 62. Pfizer Inc. Company Information Table 63. Pfizer Inc. Business Overview Table 64. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 65. Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio Table 66. Pfizer Inc. Recent Development Table 67. GlaxoSmithKline plc Company Information Table 68. GlaxoSmithKline plc Business Overview Table 69. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product Portfolio Table 71. GlaxoSmithKline plc Recent Development Table 72. Vivus LLC. Company Information Table 73. Vivus LLC. Business Overview Table 74. Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Vivus LLC. Peripherally Acting Anti-Obesity Drug Product Portfolio Table 76. Vivus LLC. Recent Development Table 77. Rhythm Pharmaceuticals Company Information Table 78. Rhythm Pharmaceuticals Business Overview Table 79. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product Portfolio Table 81. Rhythm Pharmaceuticals Recent Development Table 82. KVK Tech Inc. Company Information Table 83. KVK Tech Inc. Business Overview Table 84. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio Table 86. KVK Tech Inc. Recent Development Table 87. Gelesis Holdings Company Information Table 88. Gelesis Holdings Business Overview Table 89. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product Portfolio Table 91. Gelesis Holdings Recent Development Table 92. Currax Pharmaceuticals LLC Company Information Table 93. Currax Pharmaceuticals LLC Business Overview Table 94. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product Portfolio Table 96. Currax Pharmaceuticals LLC Recent Development Table 97. CHEPLAPHARM Arzneimittel GmbH Company Information Table 98. CHEPLAPHARM Arzneimittel GmbH Business Overview Table 99. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio Table 101. CHEPLAPHARM Arzneimittel GmbH Recent Development Table 102. Boehringer Ingelheim International GmbH Company Information Table 103. Boehringer Ingelheim International GmbH Business Overview Table 104. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio Table 106. Boehringer Ingelheim International GmbH Recent Development Table 107. North America Peripherally Acting Anti-Obesity Drug Revenue by Type (2021-2026) & (US$ Million) Table 108. North America Peripherally Acting Anti-Obesity Drug Revenue by Type (2027-2032) & (US$ Million) Table 109. North America Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2026) & (k units) Table 110. North America Peripherally Acting Anti-Obesity Drug Sales by Type (2027-2032) & (k units) Table 111. North America Peripherally Acting Anti-Obesity Drug Sales Price by Type (2021-2026) & (US$/unit) Table 112. North America Peripherally Acting Anti-Obesity Drug Sales Price by Type (2027-2032) & (US$/unit) Table 113. North America Peripherally Acting Anti-Obesity Drug Revenue by Application (2021-2026) & (US$ Million) Table 114. North America Peripherally Acting Anti-Obesity Drug Revenue by Application (2027-2032) & (US$ Million) Table 115. North America Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2026) & (k units) Table 116. North America Peripherally Acting Anti-Obesity Drug Sales by Application (2027-2032) & (k units) Table 117. North America Peripherally Acting Anti-Obesity Drug Sales Price by Application (2021-2026) & (US$/unit) Table 118. North America Peripherally Acting Anti-Obesity Drug Sales Price by Application (2027-2032) & (US$/unit) Table 119. North America Peripherally Acting Anti-Obesity Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. North America Peripherally Acting Anti-Obesity Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 121. North America Peripherally Acting Anti-Obesity Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 122. North America Peripherally Acting Anti-Obesity Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 123. North America Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026) & (k units) Table 124. North America Peripherally Acting Anti-Obesity Drug Sales by Country (2027-2032) & (k units) Table 125. North America Peripherally Acting Anti-Obesity Drug Sales Price by Country (2021-2026) & (US$/unit) Table 126. North America Peripherally Acting Anti-Obesity Drug Sales Price by Country (2027-2032) & (US$/unit) Table 127. United States Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 128. Canada Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 129. Mexico Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 130. Europe Peripherally Acting Anti-Obesity Drug Revenue by Type (2021-2026) & (US$ Million) Table 131. Europe Peripherally Acting Anti-Obesity Drug Revenue by Type (2027-2032) & (US$ Million) Table 132. Europe Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2026) & (k units) Table 133. Europe Peripherally Acting Anti-Obesity Drug Sales by Type (2027-2032) & (k units) Table 134. Europe Peripherally Acting Anti-Obesity Drug Sales Price by Type (2021-2026) & (US$/unit) Table 135. Europe Peripherally Acting Anti-Obesity Drug Sales Price by Type (2027-2032) & (US$/unit) Table 136. Europe Peripherally Acting Anti-Obesity Drug Revenue by Application (2021-2026) & (US$ Million) Table 137. Europe Peripherally Acting Anti-Obesity Drug Revenue by Application (2027-2032) & (US$ Million) Table 138. Europe Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2026) & (k units) Table 139. Europe Peripherally Acting Anti-Obesity Drug Sales by Application (2027-2032) & (k units) Table 140. Europe Peripherally Acting Anti-Obesity Drug Sales Price by Application (2021-2026) & (US$/unit) Table 141. Europe Peripherally Acting Anti-Obesity Drug Sales Price by Application (2027-2032) & (US$/unit) Table 142. Europe Peripherally Acting Anti-Obesity Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. Europe Peripherally Acting Anti-Obesity Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 144. Europe Peripherally Acting Anti-Obesity Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 145. Europe Peripherally Acting Anti-Obesity Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 146. Europe Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026) & (k units) Table 147. Europe Peripherally Acting Anti-Obesity Drug Sales by Country (2027-2032) & (k units) Table 148. Europe Peripherally Acting Anti-Obesity Drug Sales Price by Country (2021-2026) & (US$/unit) Table 149. Europe Peripherally Acting Anti-Obesity Drug Sales Price by Country (2027-2032) & (US$/unit) Table 150. Germany Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 151. France Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 152. U.K. Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 153. Italy Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 154. Russia Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 155. Spain Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 156. Netherlands Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 157. Switzerland Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 158. Sweden Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 159. Poland Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 160. China Peripherally Acting Anti-Obesity Drug Revenue by Type (2021-2026) & (US$ Million) Table 161. China Peripherally Acting Anti-Obesity Drug Revenue by Type (2027-2032) & (US$ Million) Table 162. China Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2026) & (k units) Table 163. China Peripherally Acting Anti-Obesity Drug Sales by Type (2027-2032) & (k units) Table 164. China Peripherally Acting Anti-Obesity Drug Sales Price by Type (2021-2026) & (US$/unit) Table 165. China Peripherally Acting Anti-Obesity Drug Sales Price by Type (2027-2032) & (US$/unit) Table 166. China Peripherally Acting Anti-Obesity Drug Revenue by Application (2021-2026) & (US$ Million) Table 167. China Peripherally Acting Anti-Obesity Drug Revenue by Application (2027-2032) & (US$ Million) Table 168. China Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2026) & (k units) Table 169. China Peripherally Acting Anti-Obesity Drug Sales by Application (2027-2032) & (k units) Table 170. China Peripherally Acting Anti-Obesity Drug Sales Price by Application (2021-2026) & (US$/unit) Table 171. China Peripherally Acting Anti-Obesity Drug Sales Price by Application (2027-2032) & (US$/unit) Table 172. Asia Peripherally Acting Anti-Obesity Drug Revenue by Type (2021-2026) & (US$ Million) Table 173. Asia Peripherally Acting Anti-Obesity Drug Revenue by Type (2027-2032) & (US$ Million) Table 174. Asia Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2026) & (k units) Table 175. Asia Peripherally Acting Anti-Obesity Drug Sales by Type (2027-2032) & (k units) Table 176. Asia Peripherally Acting Anti-Obesity Drug Sales Price by Type (2021-2026) & (US$/unit) Table 177. Asia Peripherally Acting Anti-Obesity Drug Sales Price by Type (2027-2032) & (US$/unit) Table 178. Asia Peripherally Acting Anti-Obesity Drug Revenue by Application (2021-2026) & (US$ Million) Table 179. Asia Peripherally Acting Anti-Obesity Drug Revenue by Application (2027-2032) & (US$ Million) Table 180. Asia Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2026) & (k units) Table 181. Asia Peripherally Acting Anti-Obesity Drug Sales by Application (2027-2032) & (k units) Table 182. Asia Peripherally Acting Anti-Obesity Drug Sales Price by Application (2021-2026) & (US$/unit) Table 183. Asia Peripherally Acting Anti-Obesity Drug Sales Price by Application (2027-2032) & (US$/unit) Table 184. Asia Peripherally Acting Anti-Obesity Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 185. Asia Peripherally Acting Anti-Obesity Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 186. Asia Peripherally Acting Anti-Obesity Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 187. Asia Peripherally Acting Anti-Obesity Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 188. Asia Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026) & (k units) Table 189. Asia Peripherally Acting Anti-Obesity Drug Sales by Country (2027-2032) & (k units) Table 190. Asia Peripherally Acting Anti-Obesity Drug Sales Price by Country (2021-2026) & (US$/unit) Table 191. Asia Peripherally Acting Anti-Obesity Drug Sales Price by Country (2027-2032) & (US$/unit) Table 192. Japan Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 193. South Korea Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 194. India Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 195. Australia Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 196. Taiwan Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 197. Southeast Asia Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 198. SAMEA Peripherally Acting Anti-Obesity Drug Revenue by Type (2021-2026) & (US$ Million) Table 199. SAMEA Peripherally Acting Anti-Obesity Drug Revenue by Type (2027-2032) & (US$ Million) Table 200. SAMEA Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2026) & (k units) Table 201. SAMEA Peripherally Acting Anti-Obesity Drug Sales by Type (2027-2032) & (k units) Table 202. SAMEA Peripherally Acting Anti-Obesity Drug Sales Price by Type (2021-2026) & (US$/unit) Table 203. SAMEA Peripherally Acting Anti-Obesity Drug Sales Price by Type (2027-2032) & (US$/unit) Table 204. SAMEA Peripherally Acting Anti-Obesity Drug Revenue by Application (2021-2026) & (US$ Million) Table 205. SAMEA Peripherally Acting Anti-Obesity Drug Revenue by Application (2027-2032) & (US$ Million) Table 206. SAMEA Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2026) & (k units) Table 207. SAMEA Peripherally Acting Anti-Obesity Drug Sales by Application (2027-2032) & (k units) Table 208. SAMEA Peripherally Acting Anti-Obesity Drug Sales Price by Application (2021-2026) & (US$/unit) Table 209. SAMEA Peripherally Acting Anti-Obesity Drug Sales Price by Application (2027-2032) & (US$/unit) Table 210. SAMEA Peripherally Acting Anti-Obesity Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 211. SAMEA Peripherally Acting Anti-Obesity Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 212. SAMEA Peripherally Acting Anti-Obesity Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 213. SAMEA Peripherally Acting Anti-Obesity Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 214. SAMEA Peripherally Acting Anti-Obesity Drug Sales by Country (2021-2026) & (k units) Table 215. SAMEA Peripherally Acting Anti-Obesity Drug Sales by Country (2027-2032) & (k units) Table 216. SAMEA Peripherally Acting Anti-Obesity Drug Sales Price by Country (2021-2026) & (US$/unit) Table 217. SAMEA Peripherally Acting Anti-Obesity Drug Sales Price by Country (2027-2032) & (US$/unit) Table 218. Brazil Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 219. Argentina Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 220. Chile Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 221. Colombia Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 222. Peru Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 223. Saudi Arabia Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 224. Israel Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 225. UAE Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 226. Turkey Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 227. Iran Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 228. Egypt Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Table 229. Key Raw Materials Table 230. Raw Materials Key Suppliers Table 231. Peripherally Acting Anti-Obesity Drug Distributors List Table 232. Peripherally Acting Anti-Obesity Drug Customers List Table 233. Research Programs/Design for This Report Table 234. Authors List of This Report Table 235. Secondary Sources Table 236. Primary Sources List of Figures Figure 1. Peripherally Acting Anti-Obesity Drug Image Figure 2. Global Peripherally Acting Anti-Obesity Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peripherally Acting Anti-Obesity Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Prescription Drugs Image Figure 5. Non-prescription Drugs Image Figure 6. Global Peripherally Acting Anti-Obesity Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Peripherally Acting Anti-Obesity Drug Market Size Share 2021 VS 2025 VS 2032 Figure 8. Online Pharmacies Image Figure 9. Hospital Pharmacies Image Figure 10. Retail Pharmacies Image Figure 11. Global Peripherally Acting Anti-Obesity Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Peripherally Acting Anti-Obesity Drug Revenue (2021-2032) & (US$ Million) Figure 13. Global Peripherally Acting Anti-Obesity Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Region (2021-2032) Figure 16. Global Peripherally Acting Anti-Obesity Drug Sales (2021-2032) & (k units) Figure 17. Global Peripherally Acting Anti-Obesity Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 18. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Peripherally Acting Anti-Obesity Drug Sales YoY (2021-2032) & (k units) Figure 20. Europe Peripherally Acting Anti-Obesity Drug Sales YoY (2021-2032) & (k units) Figure 21. China Peripherally Acting Anti-Obesity Drug Sales YoY (2021-2032) & (k units) Figure 22. Asia (Excluding China) Peripherally Acting Anti-Obesity Drug Sales YoY (2021-2032) & (k units) Figure 23. South America, Middle East and Africa Peripherally Acting Anti-Obesity Drug Sales YoY (2021-2032) & (k units) Figure 24. Global Peripherally Acting Anti-Obesity Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Peripherally Acting Anti-Obesity Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Peripherally Acting Anti-Obesity Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Type (2021-2032) Figure 30. Global Peripherally Acting Anti-Obesity Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 31. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2021-2032) Figure 33. Global Peripherally Acting Anti-Obesity Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Application (2021-2032) Figure 36. Global Peripherally Acting Anti-Obesity Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 37. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2021-2032) Figure 39. North America Peripherally Acting Anti-Obesity Drug Revenue Share by Type (2021-2032) Figure 40. North America Peripherally Acting Anti-Obesity Drug Sales Share by Type (2021-2032) Figure 41. North America Peripherally Acting Anti-Obesity Drug Revenue Share by Application (2021-2032) Figure 42. North America Peripherally Acting Anti-Obesity Drug Sales Share by Application (2021-2032) Figure 43. North America Peripherally Acting Anti-Obesity Drug Revenue Share by Country (2021-2032) Figure 44. North America Peripherally Acting Anti-Obesity Drug Sales Share by Country (2021-2032) Figure 45. Europe Peripherally Acting Anti-Obesity Drug Revenue Share by Type (2021-2032) Figure 46. Europe Peripherally Acting Anti-Obesity Drug Sales Share by Type (2021-2032) Figure 47. Europe Peripherally Acting Anti-Obesity Drug Revenue Share by Application (2021-2032) Figure 48. Europe Peripherally Acting Anti-Obesity Drug Sales Share by Application (2021-2032) Figure 49. Europe Peripherally Acting Anti-Obesity Drug Revenue Share by Country (2021-2032) Figure 50. Europe Peripherally Acting Anti-Obesity Drug Sales Share by Country (2021-2032) Figure 51. China Peripherally Acting Anti-Obesity Drug Revenue Share by Type (2021-2032) Figure 52. China Peripherally Acting Anti-Obesity Drug Sales Share by Type (2021-2032) Figure 53. China Peripherally Acting Anti-Obesity Drug Revenue Share by Application (2021-2032) Figure 54. China Peripherally Acting Anti-Obesity Drug Sales Share by Application (2021-2032) Figure 55. Asia Peripherally Acting Anti-Obesity Drug Revenue Share by Type (2021-2032) Figure 56. Asia Peripherally Acting Anti-Obesity Drug Sales Share by Type (2021-2032) Figure 57. Asia Peripherally Acting Anti-Obesity Drug Revenue Share by Application (2021-2032) Figure 58. Asia Peripherally Acting Anti-Obesity Drug Sales Share by Application (2021-2032) Figure 59. Asia Peripherally Acting Anti-Obesity Drug Revenue Share by Country (2021-2032) Figure 60. Asia Peripherally Acting Anti-Obesity Drug Sales Share by Country (2021-2032) Figure 61. SAMEA Peripherally Acting Anti-Obesity Drug Revenue Share by Type (2021-2032) Figure 62. SAMEA Peripherally Acting Anti-Obesity Drug Sales Share by Type (2021-2032) Figure 63. SAMEA Peripherally Acting Anti-Obesity Drug Revenue Share by Application (2021-2032) Figure 64. SAMEA Peripherally Acting Anti-Obesity Drug Sales Share by Application (2021-2032) Figure 65. SAMEA Peripherally Acting Anti-Obesity Drug Revenue Share by Country (2021-2032) Figure 66. SAMEA Peripherally Acting Anti-Obesity Drug Sales Share by Country (2021-2032) Figure 67. Peripherally Acting Anti-Obesity Drug Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Peripherally Acting Anti-Obesity Drug Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Prescription Drugs
  • Non-prescription Drugs
Applications
  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
Companies covered
  • Novo Nordisk A/S
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Vivus LLC.
  • Rhythm Pharmaceuticals
  • KVK Tech Inc.
  • Gelesis Holdings
  • Currax Pharmaceuticals LLC
  • CHEPLAPHARM Arzneimittel GmbH
  • Boehringer Ingelheim International GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Peripherally Acting Anti-Obesity Drug Market by Type
  3. 1.2.1 Global Peripherally Acting Anti-Obesity Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Prescription Drugs
  5. 1.2.3 Non-prescription Drugs
  6. 1.3 Peripherally Acting Anti-Obesity Drug Market by Application
  7. 1.3.1 Global Peripherally Acting Anti-Obesity Drug Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Online Pharmacies
  9. 1.3.3 Hospital Pharmacies
  10. 1.3.4 Retail Pharmacies
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Peripherally Acting Anti-Obesity Drug Market Dynamics
  1. 2.1 Peripherally Acting Anti-Obesity Drug Industry Trends
  2. 2.2 Peripherally Acting Anti-Obesity Drug Industry Drivers
  3. 2.3 Peripherally Acting Anti-Obesity Drug Industry Opportunities and Challenges
  4. 2.4 Peripherally Acting Anti-Obesity Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Peripherally Acting Anti-Obesity Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Peripherally Acting Anti-Obesity Drug Revenue by Region
  3. 3.2.1 Global Peripherally Acting Anti-Obesity Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Peripherally Acting Anti-Obesity Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Peripherally Acting Anti-Obesity Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Peripherally Acting Anti-Obesity Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Peripherally Acting Anti-Obesity Drug Sales by Region
  9. 3.4.1 Global Peripherally Acting Anti-Obesity Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Peripherally Acting Anti-Obesity Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Peripherally Acting Anti-Obesity Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Peripherally Acting Anti-Obesity Drug Revenue by Manufacturers
  2. 4.1.1 Global Peripherally Acting Anti-Obesity Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Peripherally Acting Anti-Obesity Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Peripherally Acting Anti-Obesity Drug Sales by Manufacturers
  6. 4.2.1 Global Peripherally Acting Anti-Obesity Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Peripherally Acting Anti-Obesity Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Peripherally Acting Anti-Obesity Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Peripherally Acting Anti-Obesity Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Peripherally Acting Anti-Obesity Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Peripherally Acting Anti-Obesity Drug Manufacturers, Product Type & Application
  13. 4.7 Global Peripherally Acting Anti-Obesity Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Peripherally Acting Anti-Obesity Drug Market CR5 and HHI
  16. 4.8.2 2025 Peripherally Acting Anti-Obesity Drug Tier 1, Tier 2, and Tier 3
5 Peripherally Acting Anti-Obesity Drug Market by Type
  1. 5.1 Global Peripherally Acting Anti-Obesity Drug Revenue by Type
  2. 5.1.1 Global Peripherally Acting Anti-Obesity Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Peripherally Acting Anti-Obesity Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Peripherally Acting Anti-Obesity Drug Sales by Type
  6. 5.2.1 Global Peripherally Acting Anti-Obesity Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Peripherally Acting Anti-Obesity Drug Price by Type
6 Peripherally Acting Anti-Obesity Drug Market by Application
  1. 6.1 Global Peripherally Acting Anti-Obesity Drug Revenue by Application
  2. 6.1.1 Global Peripherally Acting Anti-Obesity Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Peripherally Acting Anti-Obesity Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Peripherally Acting Anti-Obesity Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Peripherally Acting Anti-Obesity Drug Sales by Application
  6. 6.2.1 Global Peripherally Acting Anti-Obesity Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Peripherally Acting Anti-Obesity Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Peripherally Acting Anti-Obesity Drug Price by Application
7 Company Profiles
  1. 7.1 Novo Nordisk A/S
  2. 7.1.1 Novo Nordisk A/S Company Information
  3. 7.1.2 Novo Nordisk A/S Business Overview
  4. 7.1.3 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product Portfolio
  6. 7.1.5 Novo Nordisk A/S Recent Developments
  7. 7.2 Pfizer Inc.
  8. 7.2.1 Pfizer Inc. Company Information
  9. 7.2.2 Pfizer Inc. Business Overview
  10. 7.2.3 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio
  12. 7.2.5 Pfizer Inc. Recent Developments
  13. 7.3 GlaxoSmithKline plc
  14. 7.3.1 GlaxoSmithKline plc Company Information
  15. 7.3.2 GlaxoSmithKline plc Business Overview
  16. 7.3.3 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product Portfolio
  18. 7.3.5 GlaxoSmithKline plc Recent Developments
  19. 7.4 Vivus LLC.
  20. 7.4.1 Vivus LLC. Company Information
  21. 7.4.2 Vivus LLC. Business Overview
  22. 7.4.3 Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Vivus LLC. Peripherally Acting Anti-Obesity Drug Product Portfolio
  24. 7.4.5 Vivus LLC. Recent Developments
  25. 7.5 Rhythm Pharmaceuticals
  26. 7.5.1 Rhythm Pharmaceuticals Company Information
  27. 7.5.2 Rhythm Pharmaceuticals Business Overview
  28. 7.5.3 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product Portfolio
  30. 7.5.5 Rhythm Pharmaceuticals Recent Developments
  31. 7.6 KVK Tech Inc.
  32. 7.6.1 KVK Tech Inc. Company Information
  33. 7.6.2 KVK Tech Inc. Business Overview
  34. 7.6.3 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product Portfolio
  36. 7.6.5 KVK Tech Inc. Recent Developments
  37. 7.7 Gelesis Holdings
  38. 7.7.1 Gelesis Holdings Company Information
  39. 7.7.2 Gelesis Holdings Business Overview
  40. 7.7.3 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product Portfolio
  42. 7.7.5 Gelesis Holdings Recent Developments
  43. 7.8 Currax Pharmaceuticals LLC
  44. 7.8.1 Currax Pharmaceuticals LLC Company Information
  45. 7.8.2 Currax Pharmaceuticals LLC Business Overview
  46. 7.8.3 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product Portfolio
  48. 7.8.5 Currax Pharmaceuticals LLC Recent Developments
  49. 7.9 CHEPLAPHARM Arzneimittel GmbH
  50. 7.9.1 CHEPLAPHARM Arzneimittel GmbH Company Information
  51. 7.9.2 CHEPLAPHARM Arzneimittel GmbH Business Overview
  52. 7.9.3 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio
  54. 7.9.5 CHEPLAPHARM Arzneimittel GmbH Recent Developments
  55. 7.10 Boehringer Ingelheim International GmbH
  56. 7.10.1 Boehringer Ingelheim International GmbH Company Information
  57. 7.10.2 Boehringer Ingelheim International GmbH Business Overview
  58. 7.10.3 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product Portfolio
  60. 7.10.5 Boehringer Ingelheim International GmbH Recent Developments
8 North America
  1. 8.1 North America Peripherally Acting Anti-Obesity Drug Market Size by Type
  2. 8.1.1 North America Peripherally Acting Anti-Obesity Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Peripherally Acting Anti-Obesity Drug Price by Type (2021-2032)
  5. 8.2 North America Peripherally Acting Anti-Obesity Drug Market Size by Application
  6. 8.2.1 North America Peripherally Acting Anti-Obesity Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Peripherally Acting Anti-Obesity Drug Price by Application (2021-2032)
  9. 8.3 North America Peripherally Acting Anti-Obesity Drug Market Size by Country
  10. 8.3.1 North America Peripherally Acting Anti-Obesity Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Peripherally Acting Anti-Obesity Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Peripherally Acting Anti-Obesity Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Peripherally Acting Anti-Obesity Drug Market Size by Type
  2. 9.1.1 Europe Peripherally Acting Anti-Obesity Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Peripherally Acting Anti-Obesity Drug Price by Type (2021-2032)
  5. 9.2 Europe Peripherally Acting Anti-Obesity Drug Market Size by Application
  6. 9.2.1 Europe Peripherally Acting Anti-Obesity Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Peripherally Acting Anti-Obesity Drug Price by Application (2021-2032)
  9. 9.3 Europe Peripherally Acting Anti-Obesity Drug Market Size by Country
  10. 9.3.1 Europe Peripherally Acting Anti-Obesity Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Peripherally Acting Anti-Obesity Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Peripherally Acting Anti-Obesity Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Peripherally Acting Anti-Obesity Drug Market Size by Type
  2. 10.1.1 China Peripherally Acting Anti-Obesity Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2032)
  4. 10.1.3 China Peripherally Acting Anti-Obesity Drug Price by Type (2021-2032)
  5. 10.2 China Peripherally Acting Anti-Obesity Drug Market Size by Application
  6. 10.2.1 China Peripherally Acting Anti-Obesity Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2032)
  8. 10.2.3 China Peripherally Acting Anti-Obesity Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Peripherally Acting Anti-Obesity Drug Market Size by Type
  2. 11.1.1 Asia Peripherally Acting Anti-Obesity Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Peripherally Acting Anti-Obesity Drug Price by Type (2021-2032)
  5. 11.2 Asia Peripherally Acting Anti-Obesity Drug Market Size by Application
  6. 11.2.1 Asia Peripherally Acting Anti-Obesity Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Peripherally Acting Anti-Obesity Drug Price by Application (2021-2032)
  9. 11.3 Asia Peripherally Acting Anti-Obesity Drug Market Size by Country
  10. 11.3.1 Asia Peripherally Acting Anti-Obesity Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Peripherally Acting Anti-Obesity Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Peripherally Acting Anti-Obesity Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Peripherally Acting Anti-Obesity Drug Market Size by Type
  2. 12.1.1 SAMEA Peripherally Acting Anti-Obesity Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Peripherally Acting Anti-Obesity Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Peripherally Acting Anti-Obesity Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Peripherally Acting Anti-Obesity Drug Market Size by Application
  6. 12.2.1 SAMEA Peripherally Acting Anti-Obesity Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Peripherally Acting Anti-Obesity Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Peripherally Acting Anti-Obesity Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Peripherally Acting Anti-Obesity Drug Market Size by Country
  10. 12.3.1 SAMEA Peripherally Acting Anti-Obesity Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Peripherally Acting Anti-Obesity Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Peripherally Acting Anti-Obesity Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Peripherally Acting Anti-Obesity Drug Value Chain Analysis
  2. 13.1.1 Peripherally Acting Anti-Obesity Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Peripherally Acting Anti-Obesity Drug Production Mode & Process
  6. 13.2 Peripherally Acting Anti-Obesity Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Peripherally Acting Anti-Obesity Drug Distributors
  9. 13.2.3 Peripherally Acting Anti-Obesity Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst